Explore the exciting world of NovoCure (NVCR -1.20%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
NovoCure remains a strong buy due to robust earnings, a growing core business, and a promising pipeline, particularly in lung and pancreatic cancer treatments. Q4 2024 earnings showed strong revenue growth despite an EPS miss driven by a stock-comp event related to FDA approval. Updated DCF analysis yields a $34 price target, with Wall Street consensus at $35.83, indicating significant upside potential.
NovoCure's stock has risen 42% since my October recommendation, but revenue diversification outside of glioblastoma (GBM) remains a concern. Despite FDA approvals, TTFields therapy faces adoption challenges due to marginal survival benefits and high costs, impacting market growth. NovoCure's financial health shows sufficient liquidity short-term, but profit margins will compress and S&M costs will rise in 2025.
NovoCure (NVCR) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.45 per share a year ago.
NovoCure Limited (NASDAQ:NVCR ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Chairman Ashley Cordova - Chief Executive Officer Christoph Brackmann - Chief Financial Officer Frank Leonard - Executive Vice President & President, NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participants Jonathan Chang - Leerink Partners Jason Bednar - Piper Sandler Lei Huang - Wells Fargo Vijay Kumar - Evercore ISI Tanmay Patwardhan - JPMorgan Emily Bodnar - H.C. Wainwright Operator Good day, and thank you for standing by.
Cancer-targeting biotech NovoCure (NVCR -9.00%) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum was helped by price target increases from analysts.
The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances for long-term survival could become widely available next year.
Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.
On Monday, NovoCure Ltd NVCR and Zai Lab Limited ZLAB revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
Novocure said on Monday its experimental therapy extended the lives of patients with a form of advanced pancreatic cancer when combined with chemotherapy, achieving the primary goal in a late-stage trial.